IFLO I-Flow (MM)

I-FLOW CORPORATION (NASDAQ:IFLO) announced today that total revenue for the third quarter ended September 30, 2009 increased 14% to $36.7 million compared to total revenue of $32.2 million for the third quarter of 2008.

Regional Anesthesia (RA) sales of the Company's flagship ON-Q® product lines increased 11% for this year's third quarter to $27.5 million compared to $24.8 million for the third quarter of 2008. AcryMed revenues were $0.8 million for this year's third quarter compared to $1.5 million for the third quarter of 2008. The prior year quarter included $0.7 million of sales for temporary pilot production prior to the planned transfer of manufacturing responsibility to a customer. IV Infusion Therapy revenue for the third quarter of 2009 increased 41% to $8.4 million compared to $5.9 million for the third quarter of 2008.

Net income for the third quarter of 2009 increased to $0.7 million, or $0.03 per basic and diluted share. This compares to a net loss of $14.1 million, or $0.57 per basic and diluted share, for the third quarter of 2008. Transaction costs of approximately $0.8 million were incurred during the third quarter of 2009 in connection with the sale process resulting in the recently announced definitive merger agreement with Kimberly-Clark Corporation (Kimberly-Clark) providing for the acquisition of I-Flow by Kimberly-Clark for $12.65 per share in cash. The net loss for the third quarter of 2008 included a purchase accounting write-off of $11.6 million of in-process research and development charges acquired in connection with the acquisition in February 2008 of AcryMed and a $4.6 million non-cash impairment loss on the common shares of InfuSystem Holdings, Inc., formerly HAPC, Inc., owned by I-Flow.

Total revenue for the first nine months of 2009 increased 9% to $104.8 million compared to $96.0 million for the first nine months of 2008. RA sales increased 7% for this year's first nine months to $78.5 million compared to $73.5 million for first nine months of 2008. AcryMed revenues were $2.5 million for this year's first nine months compared to $3.8 million for the same period of 2008. AcryMed's revenue in the prior year period included $1.9 million of sales for temporary pilot production prior to the planned transfer of manufacturing responsibility to a customer. IV Infusion Therapy revenue for the first nine months of 2009 increased 28% to $23.8 million compared to $18.6 million for the first nine months of 2008.

The net loss for the nine months ended September 30, 2009 was $1.8 million, or $0.07 per basic and diluted share. This compares to a net loss for the nine months ended September 30, 2008 of $26.1 million, or $1.05 per basic and diluted share. Transaction costs of approximately $1.0 million were incurred during the nine months ended September 30, 2009 in connection with the sale process resulting in the recently announced definitive merger agreement with Kimberly-Clark. The net loss for the first nine months of 2008 included the purchase accounting write-off of $11.6 million for in-process research and development costs, the $4.6 million for impairment loss and $12.3 million of certain litigation and insurance charges, which consisted of a $3.5 million expense to purchase retroactive insurance policies to significantly increase the Company's product liability insurance coverage and $8.8 million in loss contingency that the Company accrued in connection with ongoing litigation.

At September 30, 2009, I-Flow reported net working capital of approximately $79.3 million, including cash, cash equivalents and short-term investments of $54.3 million, and stockholders' equity of $118.3 million.

About I-Flow

I-Flow Corporation (www.IFLO.com) is improving clinical and economic outcomes by designing, developing and marketing technically advanced, low cost delivery systems and innovative surgical products for post-surgical pain relief and surgical site care.

"Safe Harbor" Statement

Statements by the Company in this press release and in other reports and statements released by the Company are and will be forward-looking in nature and express the Company's current opinions about trends and factors that may impact future operating results. Statements that use words such as "may," "will," "should," "believes," "predicts," "estimates," "projects," "anticipates" or "expects" or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to material risks, assumptions and uncertainties, which could cause actual results to differ materially from those currently expected, and readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to publish revised forward-looking statements to reflect the occurrence of unanticipated or subsequent events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this press release that seek to advise interested parties of the risks and other factors that affect the Company's business. Interested parties should also review the Company's reports on Forms 10-K, 10-Q and 8-K and other reports that are periodically filed with or furnished to the Securities and Exchange Commission. The risks affecting the Company's business include, among others: the risk that the Offer or the Merger will not be consummated; the risk that the Company's business will be adversely impacted during the pendency of the Offer and the Merger, whether as a result of announcement of the Offer or otherwise; physician acceptance of infusion-based therapeutic regimens; potential inadequacy of insurance to cover existing and future product liability claims; implementation of the Company's direct sales strategy; successful integration of the Company's acquisition of AcryMed Incorporated and further development and commercialization of AcryMed's technologies; dependence on the Company's suppliers and distributors; the Company's continuing compliance with applicable laws and regulations, such as the Medicare Supplier Standards and the Food, Drug and Cosmetic Act, and the Medicare's and FDA's concurrence with management's subjective judgment on compliance issues, including those related to the recent FDA warning letter; the reimbursement system currently in place and future changes to that system; product availability, acceptance and safety; competition in the industry; technological changes; intellectual property challenges and claims; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves (including those related to the chondrolysis litigation); future impairment write-downs; and reliance on the success of the home health care industry. All forward-looking statements, whether made in this press release or elsewhere, should be considered in context with the various disclosures made by the Company about its business.

I-FLOW CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (in thousands, except for per share data)           Three Months Ended Nine Months Ended September 30, September 30, 2009 2008 2009 2008 Net revenues $ 36,747 $ 32,242 $ 104,756 $ 95,973 Cost of revenues   9,767   8,582     28,483     25,468   Gross profit 26,980 23,660 76,273 70,505 Operating expenses: Selling, general & administrative 22,777 22,516 68,194 70,760 Product development 2,965 1,285 7,792 3,443 Certain litigation and insurance charges -- 136 1,500 12,304

Purchased in-process research and development charges

  --   11,600     --     11,600   Total operating expenses   25,742   35,537     77,486     98,107   Operating income (loss) 1,238 (11,877 ) (1,213 ) (27,602 ) Impairment loss on investment -- (4,569 ) -- (4,569 ) Interest and other income   671   1,082     2,200     3,977   Income (loss) before income taxes 1,909 (15,364 ) 987 (28,194 ) Income tax provision (benefit)   1,239   (1,237 )   2,777     (2,105 ) Net income (loss) $ 670 $ (14,127 ) $ (1,790 ) $ (26,089 ) Net income (loss) per share of common stock: Basic $ 0.03 $ (0.57 ) $ (0.07 ) $ (1.05 )

 

Diluted

$

0.03

 

$

(0.57

)

 

$

(0.07

)

 

$

(1.05

)

Weighted average shares: Basic   24,454   24,580     24,482     24,827  

 

Diluted

 

25,001

 

 

24,580

 

 

 

24,482

 

 

 

24,827

    CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited)

(in thousands)

Sep. 30,   Dec. 31,   Sep. 30,   Dec. 31, ASSETS 2009   2008   LIABILITIES AND EQUITY 2009   2008   Cash, Equivalents & $ 54,336 $ 48,363 Current Liabilities $ 30,053 $ 23,627 Short-term Investments Accounts Receivable, Net 20,987 21,930 Inventories, Net 26,394 15,819 Long-term Liabilities 5,935 6,015 Other Current Assets 7,677 7,587 Property, Plant & Equipment, Net 4,676 4,127 Goodwill 12,233 12,233 Other Assets   27,991   38,628 Shareholders' Equity   118,306   119,045   Total $ 154,294 $ 148,687 $ 154,294 $ 148,687